English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Thirty-seven dogs with chronic canine atopic dermatitis (CAD) were treated with pentoxifylline (PTX), 25 mg/kg every 12 hours, given orally with food for at least 4 weeks. Sixteen dogs (43%) were successfully managed: with PTX alone (7 dogs, 19%), PTX with allergen-specific immunotherapy (5 dogs, 13.5%), or PTX with oral glucocorticoids (4 dogs, 10.5%), with follow-up periods of 5 months to 2.5 years. PTX was well-tolerated: one dog refused to take the drug, and one dog developed diarrhea. PTX was found to be a useful nonsteroidal antipruritic agent for many dogs with CAD.

Pentoxifylline for the Management of Pruritus in Canine Atopic Dermatitis: An Open Clinical Trial with 37 Dogs